Evidence map›Paper›PMID 36341401›Full record

ArticleFrontiers in immunology2022

Case report: Severe combined immunodeficiency with ligase 1 deficiency and Omenn-like manifestation.

Nel Dabrowska-Leonik, Agata Karolina Pastorczak, Katarzyna Bąbol-Pokora, Katarzyna Bernat-Sitarz, Barbara Piątosa, Edyta Heropolitańska-Pliszka, Magdalena M Kacprzak, Krzysztof Kalwak, Katarzyna Gul, Mirjam van der Burg and 2 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Infections in DNA Repair Defects.Pathogens (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Nel Dabrowska-LeonikDepartment of Immunology, Children's Memorial Health Institute, Warsaw, Poland.
Agata Karolina PastorczakDepartment of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland.
Katarzyna Bąbol-PokoraDepartment of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland.
Katarzyna Bernat-SitarzDepartment of Immunology, Children's Memorial Health Institute, Warsaw, Poland.
Barbara PiątosaHistocompatibility Laboratory, Children's Memorial Health Institute (IPCZD), Warsaw, Poland.
Edyta Heropolitańska-PliszkaDepartment of Immunology, Children's Memorial Health Institute, Warsaw, Poland.
Magdalena M KacprzakMedGen Medical Center, Warsaw, Poland.
Krzysztof KalwakDepartment of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Wroclaw, Poland.
Katarzyna GulDepartment of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Wroclaw, Poland.
Mirjam van der BurgDepartment of Pediatrics, Leiden University Medical Center (LUMC), Leiden, Netherlands.
Marek UssowiczDepartment of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Wroclaw, Poland.
Malgorzata PacDepartment of Immunology, Children's Memorial Health Institute, Warsaw, Poland.
Children's Memorial Health Institute · PLWroclaw Medical University · PLMedical University of Lodz · PLLeiden University Medical Center · NLMedical University of Warsaw · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DNA ligase I deficiency is an extremely rare primary immunodeficiency with only 6 patients reported in the literature. Most common manifestations include radiosensitivity, macrocytic anemia, lymphopenia with an increased percentage of gamma-delta T cells, and hypogammaglobulinemia requiring replacement therapy. Two-month-old girl with delayed development, T-B-NK+ SCID, and macrocytic anemia presented features of Omenn syndrome. Whole exome sequencing revealed two novel, heterozygous variants (c.2312 G>A, p.Arg771Gly and c.776+5G>T, p.Pro260*) in the LIG1 gene (NM_000234.1). Hematopoietic stem cell transplantation from a fully matched unrelated donor was performed at the age of 4 months using GEFA03 protocol. Mixed donor-recipient chimerism was observed, with 60-70% chimerism in the mononucleated cell compartment and over 90% in T-lymphocyte compartment, but autologous myeloid recovery. Stable CD4+ and CD8+ T-cell counts above 200/µL were achieved after 2 months, but the patient remained transfusion-dependent. Despite satisfactory immunological reconstitution, the second transplantation due to constitutional hemolytic defect has been considered. In light of possible re-transplantation, an issue of optimal conditioning protocol with sufficient myeloid engraftment is important. For the first time Omenn syndrome is described in a compound heterozygote carrying two the novel variants p.Arg771Gly and p.Pro260* in the LIG1 gene. Patients diagnosed with SCID and Omenn syndrome showing macrocytic anemia, should be screened for DNA ligase I deficiency.

Indexed as

Anemia, MacrocyticHematopoietic Stem Cell TransplantationSevere Combined ImmunodeficiencyChimerismDNA Ligase ATPFemaleHumansInfantDNA Ligase ATPhematopoietic stem cell transplantation (HCST)immunodeficiencyImmunoglobilinsligase 1Omenn-like

Identifiers

PMID36341401
PMCPMC9626757
OpenAlexW4306755467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.